Comorbidity assessment for mortality risk stratification in elderly patients with acute coronary syndrome

Authors:
M Soler Costa¹, J Nunez¹, V Ruiz², C Bonanad¹, F Formiga³, E Valero¹, M Martinez Selles⁴, F Marin⁵, A Ruescas⁶, S Garcia Blas¹, G Minana¹, E Abu-Assi⁷, H Bueno⁸, A Ariza-Sole⁹, J Sanchis¹, ¹UNIVERSITY HOSPITAL CLINIC OF VALENCIA - Valencia - Spain, ²University of Valencia, Facultad de Enfermería - Valencia - Spain, ³University Hospital of Bellvitge, Unitat de Medicina Geriátrica - Barcelona - Spain, ⁴University Hospital Gregorio Maranon, Cardiology - Madrid - Spain, ⁵Hospital Clínic Universitario Virgen de la Arrixaca, Cardiology - Murcia - Spain, ⁶University of Valencia, Fisioterapia - Valencia - Spain, ⁷Hospital Alvaro Cunqueiro, Cardiology - Vigo - Spain, ⁸University Hospital 12 de Octubre, Cardiology - Madrid - Spain, ⁹University Hospital of Bellvitge, Cardiology - Barcelona - Spain,

Topic(s):
Cardiovascular Disease in the Elderly

Citation:
This work was supported by grants from Spain’s Ministry of Economy and Competitiveness through the Carlos III Health Institute

Background
The Charlson’s is the most used comorbidity index. It comprises 19 comorbidities, some of which are infrequent in elderly patients with acute coronary syndrome (ACS), while some others are manifestations of cardiac disease rather than comorbidities.

Purpose
Our goal was to simplify comorbidity assessment in elderly non-ST-segment elevation ACS patients.

Methods
The study group consisted of 1 training (n=920, 76±7 years) and 1 testing (n=532; 84±4 years) cohorts. The end-point was all-cause mortality at 1-year follow-up. Comorbidities were assessed selecting those medical disorders other than cardiac disease that were independently associated with mortality by multivariable analysis.

Results
A total of 130 (14%) patients died in the training cohort. Six comorbidities were predictive: renal failure, anemia, diabetes, peripheral artery disease, cerebrovascular disease and chronic lung disease. The increase in the number of comorbidities yielded a gradient of risk on top of well-known clinical predictors: =3 comorbidities (27% mortality, HR=1.90, 95% CI 1.20-3.03, p=0.006); 2 comorbidities (16% mortality, HR=1.29, 95% CI 0.81-2.04, p=0.30); and 0-1 comorbidities (7.6% mortality, reference category). The discrimination accuracy (C-statistic= 0.80) and calibration (Hosmer-Lemeshow test, p=0.20) of the predictive model using the 6 comorbidities was comparable to the predictive model using the Charlson index (C-statistic=0.80; Hosmer-Lemeshow test, p=0.70). Similar results were reproduced in the testing cohort (=3 comorbidities: 24% mortality, HR=2.37, 95% CI 1.25-4.49, p=0.008; 2 comorbidities: 14% mortality, HR=1.59, 95% CI 0.82-3.07, p=0.20; 0-1 comorbidities: 7.5% reference category).
Conclusion

A simplified comorbidity assessment comprising 6 comorbidities provides useful risk stratification in elderly patients with ACS.